ClinicalTrials.gg
RecruitingNCT07349251PRHEMOUpdated Jan 16, 2026

Normal Hemostasis Values in Premature Infants

An observational study in Premature Infant, Hemostasis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 0 Months to 18 Months. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1,000
Ages
0 Months to 18 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.

Planned enrollment
8th of 99
1,000 · median 130
Started
2025
with 10 others
Observational
99 of 205
21 open now
Primary completion
2031-11
later than 44 of 45 live
Registered
197th of 205
by date
Lead sponsor
8 of 205
University Hospital, Strasbourg, France

Among the 205 studies in Premature Birth with a site in France, this one is the 8th largest by planned enrollment of the 99 observational ones that give a count, is one of 11 that started in 2025, is one of 99 observational ones, reaches primary completion later than 44 of the 45 other live ones, and was the 197th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 0 Months to 18 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Premature Birth with a site in France, or all of them as a file.
02

Study summary

This study aims to retrospectively determine, in a large cohort of apparently healthy children born before 37 weeks of gestation, the expected values of certain hemostasis parameters from birth to 18 months (when they start walking), and to determine whether or not they differ from those of full-term infants.

03

Conditions studied

  • Premature Infant, Hemostasis

Browse trials for

Keywords

  • Premature Infant
  • Neonatal Prematurity
  • Preterm Infants
  • Hemostasis
04

Who can participate

Ages eligible
0 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 18 months or younger for whom a sample was sent to the Hematology Laboratory at Strasbourg University Hospital for measurement of a hemostasis parameter

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 months or younger for whom a sample was sent to the Hematology Laboratory at Strasbourg University Hospital for measurement of a hemostasis parameter

Exclusion criteria

Exclusion Criteria:

  • Patients with incomplete data
  • Patients with a congenital hemostasis disorder (hemophilia A or B, von Willebrand disease), a coagulopathy, or hepatocellular insufficiency
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Normal hemostasis values in premature infants

    Normal hemostasis values in premature infants will be determined according to the gestational age at birth

    Time frame: Up to 6 years

07

Study locations

1 of 1 sites recruiting
  • Laboratoire d'Hématologie - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Agathe HERB, PharmD · Contactagathe.herb@chru-strasbourg.fr · 33 3 88 12 75 53
    • Agathe HERB, PharmD · Principal investigator
    • David Millard, MD · Principal investigator
    • Laurent Sattler, MD · Sub investigator
    • Jordan Wimmer, MD · Sub investigator
    • Claire Bopp, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2031, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 16, 2026
StartActual
Nov 24, 2025
Primary completionEst.
Nov 2031
CompletionEst.
Nov 24, 2031
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07349251
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Nov 24, 2025
Primary completion
Nov 2031 (estimated)
Completion
Nov 24, 2031 (estimated)
Last update
Jan 16, 2026

Study contacts

Agathe HERB, PharmD
Contact
agathe.herb@chru-strasbourg.fr
33 3 88 12 75 53

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion